CNS Pharmaceuticals, Inc.

NEWS

Image of Houston downtown park and skyline in the morning

Business

Houston’s Life Sciences Scene Continues Boosting Its Reputation

While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives.

March 13, 2025

6 min read

Angela Gabriel

IN THE PRESS

Lone Star Bio

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

December 18, 2023

5 min read

Lone Star Bio

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

December 6, 2023

4 min read

Lone Star Bio

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

November 22, 2023

7 min read

Business

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

November 15, 2023

6 min read

Lone Star Bio

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

October 19, 2023

1 min read

Lone Star Bio

CNS Pharmaceuticals’ (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date

October 11, 2023

6 min read

Lone Star Bio

CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)

September 7, 2023

6 min read

Lone Star Bio

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

1 min read

Lone Star Bio

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

August 14, 2023

7 min read

Business

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

August 14, 2023

6 min read

JOBS